Paul M. Beringer, PharmD
Interim Chair, Titus Family Department of Clinical Pharmacy
- Cystic fibrosis
- Pharmacologic therapies of CF patients
- Anti-inflammatory treatment of CF airway disease
- Improving drug dosing through novel clinical measures
- (323) 442-1402
- (626) 628-3024
PharmD, USC School of Pharmacy
Residency in Pharmacy Practice, University of California-San Francisco
Residency in Pharmacokinetics, University of California-San Francisco
Cystic fibrosis is a genetic disorder which results in defective chloride transport within the apical membrane of epithelial cells throughout the body. The principal cause of morbidity and mortality arises from chronic pulmonary infections resulting in bronchiectasis and progressive loss of lung function and eventual respiratory failure. Our group is interested in optimizing the use of pharmacologic therapies to preserve lung function and quality of life for individuals afflicted with CF.
Ongoing research projects include:
- Targeting CF Infection and Inflammation with Aerosolized Theta-defensin
- Mechanism of Macrocyclic Peptide Regulation of Pseudomonas-induced Pulmonary
- Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Dr. Beringer received his Pharm.D. degree from the USC School of Pharmacy. He completed a pharmacy practice residency and specialty residency in pharmacokinetics at the University of California at San Francisco. Currently, he is an associate professor of clinical pharmacy (USC School of Pharmacy) and associate professor of clinical medicine with the department of pulmonary and critical care medicine (USC Keck School of Medicine).
Dr. Beringer's clinical expertise is in the area of cystic fibrosis pharmacotherapy. He has authored numerous journal articles and book chapters in the area of pharmacokinetics and cystic fibrosis.